Profile data is unavailable for this security.
About the company
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.
- Revenue in CAD (TTM)1.15m
- Net income in CAD-5.34m
- Incorporated2015
- Employees8.00
- LocationAppili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
- Phone+1 (902) 442-4655
- Fax+1 (902) 442-4655
- Websitehttps://appilitherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemostemix Inc | 0.00 | -2.50m | 3.48m | -- | -- | -- | -- | -- | -0.0303 | -0.0303 | 0.00 | -0.0846 | 0.00 | -- | -- | -- | -642.29 | -599.98 | -- | -- | -- | -- | -- | -- | -- | -3.99 | -- | -- | -- | -- | 52.21 | -- | -- | -- |
| Genix Pharmaceuticals Corp | 10.83k | -4.23m | 3.55m | -- | -- | -- | -- | 328.11 | -0.0714 | -0.0714 | 0.0002 | -0.0202 | 0.0049 | 0.0502 | 1.89 | -- | -191.99 | -54.69 | -476.20 | -68.59 | 23.08 | -- | -39,036.01 | -5,345.88 | 0.0541 | -10.33 | -- | -- | -- | -50.60 | -309.27 | -- | -- | -- |
| Eve & Co Inc | 7.77m | -5.92m | 3.74m | -- | -- | -- | -- | 0.482 | -0.2055 | -0.2055 | 0.2698 | 0.733 | 0.1519 | 0.7493 | 8.73 | -- | -11.58 | -- | -24.24 | -- | -3.10 | -- | -76.22 | -- | 0.062 | -5.05 | 0.4892 | -- | 2.94 | -- | -71.97 | -- | -- | -- |
| Marvel Biosciences Corp | 0.00 | -2.51m | 4.18m | -- | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.0617 | 0.00 | -- | -- | -- | -372.25 | -- | -- | -- | -- | -- | -- | -- | -- | -26.43 | -- | -- | -- | -- | 10.29 | -- | -- | -- |
| Appili Therapeutics Inc | 1.15m | -5.34m | 4.24m | 8.00 | -- | -- | -- | 3.69 | -0.044 | -0.044 | 0.0095 | -0.0811 | 0.5047 | -- | 2.12 | -- | -234.31 | -117.41 | -- | -173.66 | -- | -- | -464.23 | -3,037.15 | -- | -5.32 | -- | -- | -75.97 | -- | 63.20 | -- | -43.04 | -- |
| Delta 9 Cannabis Inc | 70.65m | -19.60m | 4.44m | 200.00 | -- | -- | -- | 0.0629 | -0.1022 | -0.1022 | 0.3695 | -0.0393 | 0.8962 | 3.21 | 33.79 | 353,264.40 | -23.37 | -13.74 | -73.68 | -23.39 | 26.06 | 26.99 | -26.08 | -17.98 | 0.0875 | -4.29 | 1.18 | -- | 12.39 | 56.50 | 35.61 | -- | -48.22 | -- |
| Innovotech Inc | 1.24m | -176.78k | 4.68m | 16.00 | -- | 5.64 | -- | 3.77 | -0.0045 | -0.0045 | 0.0319 | 0.0213 | 1.13 | 6.10 | 7.97 | -- | -16.10 | 2.90 | -19.15 | 3.56 | 69.63 | 71.56 | -14.25 | 2.19 | 2.24 | -- | 0.00 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
| Therma Bright Inc | 25.80k | -2.88m | 4.74m | -- | -- | 2.58 | -- | 183.67 | -0.0115 | -0.0115 | 0.0001 | 0.0058 | 0.0076 | 0.0023 | 0.115 | -- | -84.40 | -220.66 | -165.23 | -444.57 | 98.45 | -- | -11,152.48 | -10,853.16 | 0.0447 | -184.52 | 0.0411 | -- | -82.86 | 11.13 | 35.93 | -- | 40.15 | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.92m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1125 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0176 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Principal Technologies Inc | 581.16k | -1.52m | 4.93m | -- | -- | 6.07 | -- | 8.48 | -0.0657 | -0.0657 | 0.0257 | 0.0247 | 0.577 | -- | 3.71 | -- | -147.50 | -- | -286.94 | -- | 42.98 | -- | -255.65 | -- | -- | -59.80 | 0.0757 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
